Moderna Inc (MRNA)vsNuvalent Inc (NUVL)
MRNA
Moderna Inc
$182.56
+5.56%
HEALTHCARE · Cap: $69.04B
NUVL
Nuvalent Inc
$123.96
0.00%
HEALTHCARE · Cap: $9.81B
Smart Verdict
WallStSmart Research — data-driven comparison
NUVL leads profitability with a 0.0% profit margin vs -141.4%. NUVL earns a higher WallStSmart Score of 25/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NUVL
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$182.56
$47.87 discount
Intrinsic value data unavailable for NUVL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Trading at 10.8x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Trading at 8.3x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NUVL
The strongest argument for NUVL centers on Altman Z-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NUVL
The primary concerns for NUVL are Price/Book, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NUVL is a value play — different risk/reward profiles.
NUVL carries more volatility with a beta of 1.14 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
NUVL generates stronger free cash flow (-92M), providing more financial flexibility.
Bottom Line
NUVL scores higher overall (25/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Nuvalent Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvalent Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology, dedicated to the development of targeted therapies for cancer patients with genetically defined diseases. Leveraging its proprietary drug discovery platform, Nuvalent aims to innovate therapeutics that specifically address genetic mutations linked to tumor proliferation, thus enhancing treatment efficacy while minimizing adverse effects. With a promising pipeline of selective therapies, the company is well-positioned to capitalize on the expanding precision oncology market, demonstrating its commitment to revolutionizing cancer treatment and improving patient outcomes.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?